Arbutus shareholders approve 2026 omnibus equity plan authorizing 16.3M shares

Arbutus Biopharma Corp

Shareholders elected all five director nominees: Androski, Beardsley, Bishop, Gline, Sawhney.
2026 Omnibus Share and Incentive Plan approved (138.9M for, 7.4M against); replaces 2011 and 2016 plans.
Plan authorizes 16,300,000 common shares for issuance as options, SARs, restricted shares, etc.
Non-binding advisory vote on executive compensation passed (137.6M for, 8.3M against).
Ernst & Young LLP ratified as independent auditor for FY 2026 (164.4M for, 2.1M against).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arbutus Biopharma Corp shareholders approved Approval of the adoption of the Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan at the 2026-05-26 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-05-26

Exact text from the filing

Proposal 2. To approve the adoption of the Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan: Votes For Votes Against Votes Abstained Broker Non-Votes 138,877,189 7,408,185 188,253 22,829,831

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arbutus Biopharma Corp shareholders approved Approval of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-05-26 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-26

Exact text from the filing

Proposal 4. To approve the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Votes For Votes Against Votes Abstained Broker Non-Votes 164,372,596 2,123,916 2,806,946 —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arbutus Biopharma Corp shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-05-26 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-05-26

Exact text from the filing

Proposal 3. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement/Circular: Votes For Votes Against Votes Abstained Broker Non-Votes 137,629,207 8,331,760 512,660 22,829,831

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arbutus Biopharma Corp shareholders approved Election of five director nominees at the 2026-05-26 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-26

Exact text from the filing

Proposal 1. To elect the five (5) director nominees named in the Proxy Statement/Circular each to serve until the 2027 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Nominee Votes For Votes Withheld Broker Non-Votes Lindsay Androski, JD, MBA, CFA 136,780,089 9,693,538 22,829,831 Robert Alan Beardsley 138,456,756 8,016,871 22,829,831 Joseph Bishop 137,372,240 9,101,387 22,829,831 Matthew Gline 126,670,273 19,803,354 22,829,831 Roger Sawhney, MD 139,299,405 7,174,222 22,829,831

View on SEC.gov

Browse all shareholder votes →

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001447028-26-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.